A
Adarx Pharmaceuticals
Providing effective and safe therapeutics to patients who suffer from intractable diseases
About Adarx Pharmaceuticals
ADARx is a biotech startup that focuses on developing innovative therapeutics using advanced RNA targeting technology. The company's mission is to transform cutting-edge scientific research into practical treatments that can save lives. ADARx operates in the biotechnology and pharmaceutical market, serving a wide range of clients including healthcare providers, research institutions, and patients suffering from various diseases.
Read full description
The company's business model revolves around the development of a multi-faceted RNA targeting platform. This platform is designed to be modality agnostic, meaning it can be used in a variety of different therapeutic applications. It includes oligonucleotides for inhibition, degradation, and editing, along with new oligonucleotide delivery technologies. In simpler terms, ADARx is creating tools that can manipulate RNA, a molecule crucial to the function of all living cells, to treat diseases.
ADARx's current research focus is on three therapeutic areas: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases. However, the company's RNA targeting platform has the potential to be applied to a wide range of diseases, and ADARx plans to continue expanding its research to include additional disease targets.
The company generates revenue by developing and commercializing its RNA targeting therapeutics. As these treatments are approved and brought to market, ADARx stands to earn significant income from their sale and use in treating various diseases.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- San Diego, United States
- Employees
- 95
- Open positions
- 7
- Dealroom signal
- 56.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Sustainable Development Goals, Rumoured $1B, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Aug 2023 | $200M | $800M | BlackRock · Invus · SR One · Vivo Capital | ↗ |
| SERIES BOther financing | Jan 2023 | $46M | $375M | SR One · Sirona Capital · OrbiMed · Lilly Asia Ventures | ↗ |
Growth signals
Latest recorded traffic for Adarx Pharmaceuticals is 7.4K monthly website visits, up 2.8% over the last three months. Adarx Pharmaceuticals's team grew 13.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
SR One
OrbiMed- SCSirona Capital
Lilly Asia Ventures
Ascenta Capital
Series B and later12 investors entered at this stage
TCGX
Bain Capital Life Sciences
BlackRock
Invus
Vivo Capital
Redmile Group
Marshall Wace
T. Rowe Price
Commodore Capital- VPVenrock Healthcare Capital Partners
Cormorant Asset Management
HBM Healthcare Investments
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adarx Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adarx Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.